Products & Tech | Page 62 of 63

Exenatide Once Weekly Provided Superior Glucose Control Compared to Byetta in Tests

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to Byetta (exenatide injection taken twice daily), in patients with type 2 diabetes...

Eli Lilly Announces The First 300-Unit Vial of Insulin

Eli Lilly and Company announced the availability of a smaller vial of insulin containing 3 mL (300 units), the first such vial in the United States. A typical vial of insulin contains 10 mL, or 1,000 "units" of insulin. Lilly developed this new smaller vial for use in hospitals based on feedback regarding the average duration of patient hospital stays.

Novo Nordisk Starts Phase 1 Trial With Oral Insulin

Novo Nordisk announced today that it has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). The aim of the trial, conducted in Germany, is to investigate the safety, tolerance, exposure of drug and effect of NN1952 oral insulin in healthy volunteers and people with type 1 and type 2 diabetes...

Phase III Trials Show Roche’s Type 2 Drug Better Than Januvia

The Swiss -based pharmaceuticals and diagnostics company Roche Holding AG announced headline results from the second and third of eight T-emerge Phase III studies for taspoglutide. Taspoglutide is the first once-weekly human glucagon-like peptide-1 (GLP-1) analogue being developed to address the important unmet needs of patients with type 2 diabetes....

Jay Cutler May Give Insulin Pump Another Chance

Jay Cutler said he'll look into wearing an insulin pump during the offseason to manage his type 1 diabetes. According to the Chicago Sun-Times Cutler tried outfitting himself with one in Denver a short time after being diagnosed but had difficulty keeping it on. "I tried it out probably a month after I was diagnosed, and we went into camp wearing it, the offseason workouts,'' he said...

Januvia (Sitagliptin) has been approved by the European Commission

According to Diabetes UK the European Commission has approved Sitagliptin ,known as Januvia, as an add-on to insulin (with or without metformin) for people with type 2 diabetes. Most type 2 diabetics can control their condition with a combination of diet, physical activity and conventional medication. Januvia was approved by the FDA in 2006...

Sirona Biochem Corp. Says New Results Show SGLT2 Sugar Blockers Could Help Fight Diabetes

In a press release dated November 17, Sirona Biochem Corp. announced that results of their latest clinical trials showed the SGLT2 inhibitor dapagliflozin lowered levels of HbA1c blood sugar significantly more than the placebo, and that it was safe and well tolerated with no serious treatment-related adverse events...

Novo’s Victoza Awaits Final FDA Approval

Novo Nordisk's CEO, Lars Sorensen, told Reuters at the Reuters Health Summit in New York that the new diabetes drug Victoza has reached the final decision stage at the U.S. FDA. Sorensen expects the drug will be approved, although "potentially all the outcomes are still possible...

Novo Nordisk: Progress Made in Oral Insulin Development

Lars Sorensen, Novo's chief executive, speaking at the Reuters Health Summit, said the company could introduce a oral insulin tablet to the market within six years. A number of companies have already tried to develop inhaled insulin, including Pfizer Inc, whose product Exubera, was discontinued in 2007. This form of insulin has raised concerns that it could cause lung damage.

Byetta Safety Label Revised

Today the FDA indicated that the safety label of Byetta would be modified to include potential kidney problems including possible kidney failure. According to the FDA website "From April 2005 through October 2008, the FDA received 78 reports of problems with kidney function in patients using Byetta." Seven million Byetta prescriptions were issued during this time, so this represents about 1 in 100,000 people being affected...